Biopharmaceutical Company’s Stock Plunges 75% After FDA Rejects New Drug

WHITE OAK, MD – JULY 20: A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
Sarah Silbiger/Getty Images

Applied Therapeutics’ stock plummeted 75 percent after the Food and Drug Administration (FDA) rejected approving govorestat as a treatment for galactosemia.

The stock closed at $2.03, reported Yahoo Finance.

The FDA issued a complete response letter (CRL) in reply to the company’s new drug application, that said the medication could not be approved in its current form due to clinical deficiencies.

Applied Therapeutic plans to address the FDA’s concerns and pursue a potential resubmission or appeal, the company said in an official statement.

While govorestat has shown positive clinical outcomes, like reduced galactitol levels and improvements in cognition and motor skills in galactosemia patients, the FDA review highlighted unresolved issues.

The company also plans to submit a new drug application for govorestat in treating sorbitol dehydrogenase deficiency in 2025.

Read original article here

Denial of responsibility! Pioneer Newz is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.

Leave a Comment